<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088174</url>
  </required_header>
  <id_info>
    <org_study_id>SHR8735-111</org_study_id>
    <nct_id>NCT05088174</nct_id>
  </id_info>
  <brief_title>A Trial of Hetrombopag in Healthy Subjects</brief_title>
  <official_title>A Single-Center, Single-Arm, Open-Label, Self-Controlled, Drug-Drug Interaction Study of Hetrombopag Olamine and Ciclosporin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, single-arm, open-label, self-controlled, phase I clinical study. A&#xD;
      total of 26 male or female healthy subjects are intended to be enrolled to evaluate the PK&#xD;
      drug-drug interaction between ciclosporin and hetrombopag.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2020</start_date>
  <completion_date type="Actual">October 22, 2020</completion_date>
  <primary_completion_date type="Actual">October 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak hetrombopag plasma concentration (Cmax)</measure>
    <time_frame>0-120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the plasma hetrombopag concentration vs time curve (AUC0-120)</measure>
    <time_frame>0-120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma hetrombopag concentration vs time curve (AUC0-inf)</measure>
    <time_frame>0-infinity</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)</measure>
    <time_frame>0-120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life Associated With the Terminal Slope (t½)</measure>
    <time_frame>0-120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of volunteers with adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to Day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Sever Aplastic Anaemia</condition>
  <arm_group>
    <arm_group_label>D1：hetrombopag single dose，D11-D15：cyclosporine,D16 combination use of hetrombopag and cyclosporine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule</intervention_name>
    <description>Drug:&#xD;
Hetrombopag Olamine Tablet Ciclosporin Soft Capsule</description>
    <arm_group_label>D1：hetrombopag single dose，D11-D15：cyclosporine,D16 combination use of hetrombopag and cyclosporine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily sign the informed consent form prior to any study-related activities,&#xD;
             understand the procedures and methods of the study, and agree to complete this study&#xD;
             in strict accordance with the clinical study protocol;&#xD;
&#xD;
          2. Male or female subjects aged 18-55 years (inclusive);&#xD;
&#xD;
          3. Body mass index (BMI) between 18 and 26 kg/m2 (inclusive);&#xD;
&#xD;
          4. Normal or abnormal but not clinically significant physical examination and laboratory&#xD;
             test results; normal or abnormal but not clinically significant ECG;&#xD;
&#xD;
          5. Have no plan for pregnancy and agree to take effective contraceptive measures from&#xD;
             signing of informed consent form until 6 months after the last dose;&#xD;
&#xD;
          6. Able to maintain a consistency of good communication with the investigators, and&#xD;
             understand and comply with all the requirements of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any previous or current serious clinical conditions of the circulatory system,&#xD;
             endocrine system, nervous system, digestive system, respiratory system, and&#xD;
             hematological, immunological, psychiatric and metabolic abnormalities, or any disease&#xD;
             that may interfere with the results of this study;&#xD;
&#xD;
          2. History of deep venous thrombosis or other thrombotic disorders;&#xD;
&#xD;
          3. QTc &gt; 450 ms in males or QTc &gt; 460 ms in females through 12-lead ECG examination with&#xD;
             clinical significance per the investigator's judgment at screening;&#xD;
&#xD;
          4. Positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody&#xD;
             (trust), or HIV antibody;&#xD;
&#xD;
          5. Positive pregnancy test result;&#xD;
&#xD;
          6. Allergic constitution, or allergy to any component of hetrombopag olamine tablets and&#xD;
             ciclosporin capsules;&#xD;
&#xD;
          7. Have received surgery within 4 weeks before the first study administration, or plan to&#xD;
             undergo surgery during the course of the study;&#xD;
&#xD;
          8. Have taken any drug that alters liver enzyme activity within 28 days before the first&#xD;
             study administration or during the study;&#xD;
&#xD;
          9. Have taken any prescription drug, over-the-counter drug, herbal medicine, or health&#xD;
             supplements within 14 days before the first study administration, or within 5&#xD;
             half-lives of the drug at screening; plan to take non-study drugs or health&#xD;
             supplements during the study;&#xD;
&#xD;
         10. Consumption of grapefruit or grapefruit-containing products, foods or beverages&#xD;
             containing caffeine, xanthine, or alcohol within 48 h before the first study&#xD;
             administration; strenuous exercise, or other factors that affect drug absorption,&#xD;
             distribution, metabolism, and excretion;&#xD;
&#xD;
         11. Have participated in any drug clinical trial and have been treated with any&#xD;
             investigational drug or medical device within 3 months before the first study&#xD;
             administration (per the date of signing the informed consent form);&#xD;
&#xD;
         12. Have blood donation (or blood loss) of ≥ 400 mL or have received blood transfusion&#xD;
             within 3 months before screening;&#xD;
&#xD;
         13. Unable or unwilling to comply with the lifestyle requirements in the protocol;&#xD;
&#xD;
         14. Addicted to smoking (≥ 5 cigarettes per day within 1 month before screening);&#xD;
&#xD;
         15. Average daily alcohol consumption of &gt; 15 g for females (e.g., 145 mL of wine, 497 mL&#xD;
             of beer, or 43 mL of low-alcohol liquor) and &gt; 25 g for males (e.g., 290 mL of wine,&#xD;
             994 mL of beer, or 86 mL of low-alcohol liquor) within 1 month before screening;&#xD;
&#xD;
         16. History of drug abuse, history of drug dependence, or drug abuse screening positive&#xD;
             (drugs include morphine, methamphetamine, ketamine, ecstasy (dimethylene&#xD;
             dioxyamphetamine), and cannabis (tetrahydrocannabinol)) (consultation and&#xD;
             examination), or history of drug abuse within the past five years or have used&#xD;
             narcotics within 3 months before the study;&#xD;
&#xD;
         17. Potentially unable to complete the study for other reasons or judged by the&#xD;
             investigator as not suitable for the study.&#xD;
&#xD;
         18. Intolerant to venipuncture, or history of hemophobia or fear of needles;&#xD;
&#xD;
         19. Have special dietary requirements and unable to accept a standardized diet;&#xD;
&#xD;
         20. Acute disease from screening to first study administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Second University Hospital Ethics Committee</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

